Similar articles

• Intravenous labetalol in the treatment of severe hypertension.

  Cumming AM, Brown JJ, Lever AF, Robertson JI. Cumming AM, et al. Br J Clin Pharmacol. 1982 Jun;13(1 Suppl):93S-96S. doi: 10.1111/j.1365-2125.1982.tb01895.x. Br J Clin Pharmacol. 1982. PMID: 7093105 Free PMC article.
• [Malignant pheochromocytoma: blood pressure controlled by labetalol].

  Sugano O, Hirano J, Hirano K, Kubota Y, Numasawa K, Kawamura S. Sugano O, et al. Nihon Hinyokika Gakkai Zasshi. 1984 Mar;75(3):523-7. Nihon Hinyokika Gakkai Zasshi. 1984. PMID: 6471663 Japanese. No abstract available.
• Labetalol in the treatment of a patient with phaechromocytoma: a case report.

  Bailey RR. Bailey RR. Br J Clin Pharmacol. 1979;8(Suppl 2):141S-142S. Br J Clin Pharmacol. 1979. PMID: 526394 Free PMC article. No abstract available.
• Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

  Prichard BN. Prichard BN. Drugs. 1984;28 Suppl 2:51-68. doi: 10.2165/00003495-198400282-00005. Drugs. 1984. PMID: 6151891 Review.
• [Protective effect of alpha beta-blockers on hypertensive target-organ damage].

  Kai H, Imaizumi T. Kai H, et al. Nihon Rinsho. 2004 Mar;62 Suppl 3:587-90. Nihon Rinsho. 2004. PMID: 15171441 Review. Japanese. No abstract available.